Search company, investor...

Concentric Medical

Founded Year



Acquired | Acquired

Total Raised






About Concentric Medical

Concentric Medical, founded in 1999, is a medical device company committed to opening the pathway to stroke treatment. The company is the first to complete a pivotal trial and receive FDA clearance for a device for the removal of blood clots from patients experiencing an ischemic stroke. The Merci (Mechanical Embolus Removal in Cerebral Ischemia) Retriever is a therapy that removes the clot, restores blood flow and offers hope for ischemic stroke patients with no other options.

Headquarters Location

301 East Evelyn Avenue

Mountain View, California, 94041,

United States


Missing: Concentric Medical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Concentric Medical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Concentric Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Concentric Medical is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,312 items

Companies that received FDA De Novo clearances since 2010. Companies tagged as #FDADeNovos

Concentric Medical Patents

Concentric Medical has filed 30 patents.

patents chart

Application Date

Grant Date


Related Topics




Angiology, Electromagnetism, Vascular diseases, Actuators, Implants (medicine)


Application Date


Grant Date



Related Topics

Angiology, Electromagnetism, Vascular diseases, Actuators, Implants (medicine)



Latest Concentric Medical News

Hyperfine Appoints Maria Sainz as President, CEO

Oct 10, 2022

Sainz has led medical device companies AEGEA, Cardiokinetix, and Concentric Medical. Sam Brusco, Associate Editor10.10.22 Hyperfine has named medical device industry veteran Maria Sainz as its new president and CEO beginning October 24. Interim president CEO Scott Huennekens will remain as executive chair of the board. Sainz held president and CEO positions at AEGEA Medical (bought by CooperSurgical in 2021), Cardiokinetix, and Concentric Medical (bought by Stryker in 2011). She has over 30 years of medical device industry experience and has served on Hyperfine’s board since the company’s Nasdaq listing. “I am excited and honored to lead the next phase of Hyperfine’s growth as we broaden the adoption of Swoop technology, improving access to MR imaging around the world,” Sainz told the press. “With over 90 systems installed globally and our growing value proposition in the ICU and neurocritical care settings, we have established a strong foundation to drive forward commercial momentum. I am eager to join the Hyperfine team as we expand to additional hospitals and continue increasing our clinical applications to improve patient care in mature and emerging healthcare systems.”   “We are very pleased to name Ms. Sainz president and CEO of Hyperfine. She carries a successful track record of execution and shareholder value creation across medical device businesses, and her decades of experience are immensely valuable,” said Huennekens. “I am confident in her ability to manage the business with a disciplined approach to spending while leading Hyperfine into its next phase of growth by expanding the Swoop commercial footprint to new sites of care.”   “Ms. Sainz has the experience, judgement, and speed needed to ensure that Hyperfine continues to define and own the field of portable MRI. Since inception, Hyperfine has been a technical and AI powerhouse, and now Hyperfine needs to be a commercial force. Ms. Sainz brings the experience, intelligence, and capability to the table to execute that plan,” said Dr. Jonathan Rothberg , Hyperfine’s founder and Vice Chairman. Trending

Concentric Medical Frequently Asked Questions (FAQ)

  • When was Concentric Medical founded?

    Concentric Medical was founded in 1999.

  • Where is Concentric Medical's headquarters?

    Concentric Medical's headquarters is located at 301 East Evelyn Avenue, Mountain View.

  • What is Concentric Medical's latest funding round?

    Concentric Medical's latest funding round is Acquired.

  • How much did Concentric Medical raise?

    Concentric Medical raised a total of $19.3M.

  • Who are the investors of Concentric Medical?

    Investors of Concentric Medical include Stryker, SV Health Investors, New Enterprise Associates, New Venture Partners, ProQuest Investments and 10 more.

  • Who are Concentric Medical's competitors?

    Competitors of Concentric Medical include MicroTransponder, CoAxia, Cameron Health, Micrus Endovascular, nFocus Neuromedical and 12 more.

Compare Concentric Medical to Competitors

NeoChord Logo

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.


Atritech has developed the WATCHMAN, an implantable device designed to capture clots that may form in the left atrial appendage of patients with atrial fibrillation, thereby aiming to reduce the risk of stroke and eliminating the need for long-term use of blood thinning medications.

Tayside Flow Technologies

Tayside Flow Technologies Limited is a medical device company. It had developed the Spiral Laminar Flow Vascular Arteriovenous Graft.Tayside Flow Technologies Ltd (TFT) is a medical technology company focussed on the development of cardiovascular devices based on a new understanding of blood flow dynamics, Spiral Laminar Flow.


MetaCure is a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.